Specifically, as RA-induced RANKL expression is a major factor in joint destruction, chemical or biological agents capable of inhibiting RANKL expression have been developed to prevent joint destruction in patients with RA [10]. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.